Top Markets
Coin of the day
Cotinga Pharmaceuticals Inc. Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Inc.

COTQF
Rang in Aktien #42319
Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused... Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene. The company is also progressing COTI-219, another oral small molecule compound, specifically engineered to inhibit mutant forms of KRAS without affecting the normal functions of the KRAS gene. In collaboration with St. Vincent's University Hospital, Cotinga is conducting research to evaluate COTI-2 when combined with eribulin for patients suffering from triple-negative metastatic breast cancer. The company, which was previously known as Critical Outcome Technologies Inc., rebranded to Cotinga Pharmaceuticals Inc. in January 2018. Its corporate base is situated in Toronto, Canada.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2026-07-02
Marktkapitalisierung
$2.20K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel Cotinga Pharmaceuticals Inc. (COTQF)

Kategorie

Kursverlauf für Cotinga Pharmaceuticals Inc. (COTQF)
Höchster Schlusskurs: $0.00 am 2026-07-01

Niedrigster Schlusskurs: $0.42 am 2009-09-01
Kursverlauf der Aktie von Cotinga Pharmaceuticals Inc. von 2009 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 0.00%
2025 0.00%
2024 0.00%
2023 0.00%
2022 900.00%
2021 -99.99%
2020 3,089.48%
2019 12.40%
2018 -95.52%
2017 -73.25%
2016 53.81%
2015 3.50%
2014 33.09%
2013 16.94%
2012 -61.29%
2011 145.58%
2010 -65.69%
2009 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$527.87 36.13%
US
$873.57 37.02%
NL
$736.38 8.73%
CH
$263.09 20.45%
BE
$1.07K -5.56%
KR